EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study

Mikolaj Swiderski iD, Sarah Lewis, Yana Vinogradova iD, Matthew J Ridd iD, Zenas Z N Yiu iD, Antonia Lloyd-Lavery iD, Vibhore Prasad iD, Sonia Gran iD

British Journal of Dermatology · 17.10.2025 · 193 (5) · 889-897

DOI: 10.1093/bjd/ljaf237 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 19.06.2025. Verfasst von Mikolaj Swiderski und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, COVID-19, Urticaria, Herpes Zoster. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several population-based studies have reported an increased risk of serious skin conditions following COVID-19 vaccinations, but their population samples were not representative. Accurately estimating these risks is important for understanding vaccine hesitancy and improving clinical practice.

Objectives

To compare the incidence rates (IRs) of bullous pemphigoid (BP), herpes zoster (HZ) and urticaria before and after the UK’s COVID-19 vaccination programme started.

Methods

We conducted a population-based cohort study using electronic healthcare records from the Clinical Practice Research Datalink (1 January 2019–31 May 2023). We estimated monthly IRs (cases/100 000 person-years) for BP, HZ and urticaria. Using interrupted time series analysis, we compared changes in the IR slopes before and after the vaccine programme started (intervention). Sensitivity analyses were adjusted for COVID-19 lockdowns and total general practitioner (GP) appointments.

Results

In total, 16 156 639 adults (aged ≥ 18 years) registered at a general practice between 1 January 2019 and 31 May 2023 (BP, n = 3506; HZ, n = 129 668; urticaria, n = 63 320). The BP IR (cases/100 000 person-years) did not change postintervention vs. the preintervention period. We did not detect pre- and postintervention slopes. Sensitivity analysis results were similar. Preintervention, there was a downward slope for the HZ IR [–4.44, 95% confidence interval (CI) –5.54 to –3.35; P < 0.005]. The HZ IR increased postintervention vs. the preintervention period (5.15, 95% CI 3.43–6.88; P < 0.005). Despite the increase in the HZ IR, we found no evidence of a postintervention slope. Sensitivity analysis results were similar. Preintervention, there was a downward slope for the urticaria IR (–3.42, 95% CI –4.13 to –2.70; P < 0.005). The urticaria IR increased postintervention vs. the preintervention period (4.40, 95% CI 3.27–5.53; P < 0.005), resulting in an upward slope (0.98, 95% CI 0.43–1.52; P < 0.005). However, after accounting for lockdowns or GP appointments, the upward postintervention slope was no longer apparent.

Conclusions

While the BP IR did not change following the COVID-19 vaccine programme in the UK, we detected increased IRs for HZ and urticaria. However, these increases were modest, and, for many, the benefits of vaccination will probably outweigh the potential risks. Future research should use individual patient-level studies (e.g. self-controlled case series) to determine whether the increases in HZ and urticaria IRs are driven by COVID-19 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousCOVID-19UrticariaHerpes ZosterCOVID-19 VaccinesHumansUnited KingdomIncidenceMaleFemaleMiddle AgedAgedAdultAdolescentAged, 80 and overYoung AdultSARS-CoV-2Cohort StudiesVaccinationImmunization Programs

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • School of Medicine, University of Nottingham, Nottingham, UK.
  • Centre for Applied Excellence in Skin & Allergy Research, University of Bristol, Bristol, UK.
  • Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, the University of Manchester, Manchester, UK.
  • Department of Dermatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • School of Life Course and Population Sciences, King's College London, London, UK.

ORCID-Profile: Mikolaj Swiderski, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, Vibhore Prasad, Sonia Gran

Zitieren

APA

Swiderski, M., Lewis, S., Vinogradova, Y., Ridd, M. J., Yiu, Z. Z. N., Lloyd-Lavery, A., Prasad, V., & Gran, S. (2025). Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study. British Journal of Dermatology, 193(5), 889-897. https://doi.org/10.1093/bjd/ljaf237

Vancouver

Swiderski M, Lewis S, Vinogradova Y, Ridd MJ, Yiu ZZN, Lloyd-Lavery A, et al. Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study. British Journal of Dermatology. 2025;193(5):889-897. doi:10.1093/bjd/ljaf237

BibTeX
@article{Swiderski2025,
  author = {Swiderski, Mikolaj and Lewis, Sarah and Vinogradova, Yana and Ridd, Matthew J and Yiu, Zenas Z N and Lloyd-Lavery, Antonia and Prasad, Vibhore and Gran, Sonia},
  title = {Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study},
  journal = {British Journal of Dermatology},
  year = {2025},
  volume = {193},
  number = {5},
  pages = {889--897},
  doi = {10.1093/bjd/ljaf237}
}
Kostenlos starten →